Clevudine
- Generic Name
- Clevudine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C10H13FN2O5
- CAS Number
- 163252-36-6
- Unique Ingredient Identifier
- IN51MVP5F1
- Indication
用于慢性乙型肝炎(简称乙肝)的治疗。
- Associated Conditions
- Viral Hepatitis B
- Associated Therapies
- -
Switching Study From Lamivudine to Clevudine in the Chronic Hepatitis B Patients
- First Posted Date
- 2007-11-15
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 100
- Registration Number
- NCT00558493
- Locations
- 🇰🇷
Youngnam University Medical Center, Daegu, Korea, Republic of
Safety and Efficacy Study of Clevudine Compared With Clevudine and Vaccine in Patient With HBeAg(+) Chronic HBV
- Conditions
- First Posted Date
- 2007-07-13
- Last Posted Date
- 2010-12-22
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 70
- Registration Number
- NCT00501124
- Locations
- 🇰🇷
Chungbuk National University Hospital, Gaesin-dong, Cheongju Si Heungdeok-gu, Chungcheongbuk-Do, Korea, Republic of
🇰🇷Dankook University Hospital, Anseo-dong, Cheonan Si, Chungcheongnam-Do, Korea, Republic of
🇰🇷The Catholic University of Korea, Daejeon St. Mary's Hospital, Daeheung-dong, Jung-gu, Daejeon, Korea, Republic of
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With Chronic Hepatitis Due to Hepatitis B Virus
- Conditions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Pharmasset
- Registration Number
- NCT00496158
- Locations
- 🇺🇸
Advanced Clinical Research Institution, Anaheim, California, United States
🇺🇸Saint Louis University, St. Louis, Missouri, United States
🇺🇸Methodist Transplant Physicians, Dallas, Texas, United States
Efficacy and Safety of Clevudine Compared With Adefovir in Patients With HBeAg Positive Chronic Hepatitis Due to Hepatitis B Virus
- Conditions
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2009-04-27
- Lead Sponsor
- Pharmasset
- Registration Number
- NCT00496002
- Locations
- 🇺🇸
Asheville Gastroenterology, Asheville, North Carolina, United States
🇺🇸Baylor University Medical Center, Dallas, Texas, United States
🇦🇺Royal Prince Alfred Hospital, Sydney, New South Wales, Australia
Safety and Antiviral Activity of Clevudine in Patients Who Have Completed the L-FMAU-301 or L-FMAU-302 Trials
- Conditions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Bukwang Pharmaceutical
- Registration Number
- NCT00362505
- Locations
- 🇰🇷
Chungnam National University Hospital, Daesa-dong, Jung-gu, Daechon, Korea, Republic of
🇰🇷Keimyumg University Dongsan Medical Center, Jung-gu,, Daegu, Korea, Republic of
🇰🇷Kyungpook National University Medical Hospital, Jung-gu, Daegu, Korea, Republic of
Compare the Efficacy and Safety of 48-week Treatment With Clevudine 30mg Versus Lamivudine 100mg for CHB Infection
- Conditions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2012-07-26
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 92
- Registration Number
- NCT00362635
- Locations
- 🇭🇰
Queen Mary Hospital, Road, Hong Kong
🇭🇰Alice Ho Miu Ling Nethersole Hospital, Tai Po, New Territories, Hong Kong
Safety and Efficacy Study of Retreated Clevudine in Chronic HBV Patients Who Received Clevudine in L-FMAU-201
- Conditions
- First Posted Date
- 2006-08-10
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 33
- Registration Number
- NCT00362700
- Locations
- 🇰🇷
Yongdong Severance Hospital, Dogok-dong, Kangnam-gu, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Ilwon-dong, Songpa-gu, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Pungnab2-dong, Songpa-Gu, Seoul, Korea, Republic of
Safety and Efficacy Study of L-FMAU in Chronic HBV Patients of L-FMAU-201 Placebo Group
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-10-17
- Lead Sponsor
- Bukwang Pharmaceutical
- Registration Number
- NCT00313261
- Locations
- 🇰🇷
Ewha Womans University Hospital, Mok-dong, Yangchon-Gu, Seoul, Korea, Republic of
🇰🇷Asan Medical Center, Pungnab2-dong, Songpa-Gu, Seoul, Korea, Republic of
🇰🇷Seoul National University, Yeongeon-dong, Jongno-Gu, Seoul, Korea, Republic of
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patient With Chronic HBV
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 180
- Registration Number
- NCT00313287
- Locations
- 🇰🇷
St. Mercy's Hospital, Bupyoung-dong, Bupyoung-gu, Incheon, Korea, Republic of
🇰🇷Chonnam National University Hospital, Hak-1-dong, Dong-gu, Gwangju-si, Korea, Republic of
🇰🇷Kangbuk Samsung Hospital, Pyoung-dong, Chongro-gu, Seoul, Korea, Republic of
Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Bukwang Pharmaceutical
- Target Recruit Count
- 80
- Registration Number
- NCT00313274
- Locations
- 🇰🇷
St. Mary's Hospital, Seoul, Yungdungpo-Gu, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Dae myoung-dong, Nam-gu, Taegu, Korea, Republic of
🇰🇷St. Mercy's Hospital, Bupyoung-dong, Bupyoung-gu, Incheon, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.